We are the world leaders in the discovery and development of novel, first-in-class, small molecule therapeutics targeting SH2-containing inositol-5′-phosphatase (“SHIP1”) for the treatment of inflammatory disease. Our lead clinical candidate, AQX-1125, is a highly active and selective small molecule allosteric activator of SHIP1 suitable for once-daily oral dosing as a pill. AQX-1125 is currently being investigated in two Phase IIa proof-of-concept studies that we anticipate completing in 2012.
AQX-1125 is our lead candidate from our most advanced research program, our SHIP1 activator program, and has demonstrated broad anti-inflammatory activity both in vitro and in vivo. AQX-1125 possesses many desirable drug-like properties and has generated promising clinical data. We are now evaluating several closely related analogs that have unique properties for different routes of administration and we are advancing these follow-on products into IND-enabling studies.